Intellia Therapeutics is trading 7.76% up at $12.58 after biotech sentiment improved following positive Phase 3 personalized mRNA cancer-vaccine results from Moderna and Merck.
- No clear company-specific announcement was identified for August 19, 2026.
- The move appears sector-driven rather than linked to Intellia’s August 6 earnings or August 7 employee-inducement filing.